This report was first published by Endpoints News. To see the original version, click here
Biotech IPOs are on the comeback trail.
Fibrosis-focused Agomab Therapeutics and eye disease company SpyGlass Pharma will go public on Friday in respective $200 million and $150 million Nasdaq debuts. Those floats follow listings earlier this week from two late-stage biotechs: Roger Perlmutter-led Eikon Therapeutics and oral Rogaine developer Veradermics.
您已阅读10%（446字），剩余90%（4126字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。